RxDoctor Payments DataLook up a doctor →

Danielle Becker, MD

Epilepsy · Columbus, OHNPI 1134381759

Payments from drug & device makers

$1,614,815in general payments, 2019–2025

Across 1,664 payments — averaging $970.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$555K
  • Neurelis, Inc.$390K
  • Livanova USA, Inc.$371K
  • Jazz Pharmaceuticals Inc.$157K
  • Neuropace, Inc.$106K
  • Supernus Pharmaceuticals, Inc.$16K
  • plus $19K from 11 others

What the payments were for

  • Consulting fees$172,91611%
  • Speaking & faculty fees$1,203,16876%
  • Grants$9,0001%
  • Travel & lodging$160,44510%
  • Food & beverage$37,2982%
  • Education$5,6700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614,815 in reported general payments places this provider in the 95th percentile of 21 epilepsy providers in Ohio.

See all epilepsy providers in Ohio

Medicare billing

Part B allowed, 2024
$28,593
Medicare patients
116
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate67$90,583
ValtocoDiazepam22$27,682
VimpatLacosamide14$20,181
KeppraLevetiracetam12$15,559
Lamotrigine ErLamotrigine18$9,397
Lacosamide51$6,812
Levetiracetam96$3,343
CarbatrolCarbamazepine11$2,548
Clobazam17$2,344
Lamotrigine55$1,145
Zonisamide17$1,128
Levetiracetam ErLevetiracetam24$636
Divalproex Sodium15$524
Topiramate16$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$555,426$90,58367 claims
Neurelis, Inc.Valtoco$390,220$27,68222 claims
UCB, Inc.Vimpat$13,677$20,18114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 epilepsy providers in Ohio.

Other epilepsy in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →